Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial

NCT02640534 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT02640534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02640534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
June 10, 2016
Completion date
March 16, 2023
Enrollment
169 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, prostate cancer